Mr Tanner Lee Frey, PHYSICIAN ASSISTANT | |
1034 N 500 W, Provo, UT 84604-3380 | |
(801) 358-1076 | |
Not Available |
Full Name | Mr Tanner Lee Frey |
---|---|
Gender | Male |
Speciality | Physician Assistant |
Location | 1034 N 500 W, Provo, Utah |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1164909479 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207PE0004X | Emergency Medicine - Emergency Medical Services | 1153249 (Utah) | Secondary |
363A00000X | Physician Assistant | 10931513-1206 (Utah) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mr Tanner Lee Frey, PHYSICIAN ASSISTANT 245 W 500 N, Lindon, UT 84042-1302 Ph: (801) 358-1076 | Mr Tanner Lee Frey, PHYSICIAN ASSISTANT 1034 N 500 W, Provo, UT 84604-3380 Ph: (801) 358-1076 |
News Archive
BioDelivery Sciences International, Inc. announced that the U.S. Food and Drug Administration has approved the company's Supplemental New Drug Application (sNDA) for a manufacturing specification change for BUNAVAIL (buprenorphine and naloxone) buccal film (CIII).
Treating major depression can be quite a puzzle, and a newly published UCLA study suggests medication is just one of many potential pieces.
But a new study by researchers at Loyola University Health System and other centers casts doubt on the TB spore theory. Researchers were unable to detect spores in TB cultures and demonstrated that the TB bacterium doesn't even contain genes related to those needed to produce spores. Researchers also failed to find any spores in frogs infected with TB bacteria, which would have been expected if TB bacteria produced spores in the course of infection.
Quark Pharmaceuticals, Inc., a pharmaceutical company engaged in the discovery and development of RNAi-based therapeutics, today announced that it has received results from a prospective randomized Phase 2 trial, the DEGAS study.
Enzon Pharmaceuticals, Inc. today announced its financial results for the first quarter of 2010. During the quarter, the Company completed the sale of its specialty pharmaceutical business. This transaction has now transformed the Company, both financially and operationally, into a biopharmaceutical company dedicated to the discovery and development of oncology medicines.
› Verified 3 days ago